FLT3 and acute myeloid leukemia: A recently published subgroup analysis of the EBMT group indicated that the survival advantages associated with BuMel conditioning were limited to poor-risk or FLT3 mutated AML patients whereas the outcome in favorable or intermediate risk AML was comparable [44].